# Mechanism of PERK - eIF2a Pathways in Intestinal Mucosal Barrier of IBS-D and the Role "Metabolism Ingredients" of Tongxieyaofang

> **NCT04122586** · NA · UNKNOWN · sponsor: **Xiyuan Hospital of China Academy of Chinese Medical Sciences** · enrollment: 60 (estimated)

## Conditions studied

- IBS (Irritable Bowel Syndrome)

## Interventions

- **DRUG:** Tongxieyaofang(granule)

## Key facts

- **NCT ID:** NCT04122586
- **Lead sponsor:** Xiyuan Hospital of China Academy of Chinese Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-08-01
- **Primary completion:** 2020-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2020-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04122586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04122586, "Mechanism of PERK - eIF2a Pathways in Intestinal Mucosal Barrier of IBS-D and the Role "Metabolism Ingredients" of Tongxieyaofang". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04122586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*